Population Effectiveness of HPV Vaccination on Cervical Cancer Prevention in the U.S. Project #3 Cosette M. Wheeler, Ph.D.

Similar documents
Risk : How does it define cervical cancer screening?

Effect of human papillomavirus vaccination on cervical cancer screening in Alberta

Molecular Triage: Partial and Extended Genotyping and More!

Implementation of a Research-Robust Colposcopy Management Program within the Electronic Medical Record System

Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening

Natural History of HPV Infections 15/06/2015. Squamous cell carcinoma Adenocarcinoma

Woo Dae Kang, Ho Sun Choi, Seok Mo Kim

News. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM

Cervical Screening for Dysplasia and Cancer in Patients with HIV

Objectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies

Clinical Relevance of HPV Genotyping. A New Dimension In Human Papillomavirus Testing. w w w. a u t o g e n o m i c s. c o m

Making Sense of Cervical Cancer Screening

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

Clinical outcomes after conservative management of CIN1/2, CIN2, and CIN2/3 in women ages years

Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure

HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options

Colposcopy. Attila L Major, MD, PhD

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA

I have no financial interests in any product I will discuss today.

Cervical Cancer 4/27/2016

Eradicating Mortality from Cervical Cancer

Over-diagnoses in Cytopathology: Is histology the gold standard?

Samuel B. Wolf, D.O., F.A.C.O.G. Emerald Coast Obstetrics and Gynecology Panama City Florida

What is a Pap Smear and What do the results mean? Maria E Daheri RN Cervical Nurse Case Harris Health System

European Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs

New Mexico Department of Health Influenza & Respiratory Disease Report

Cervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH

CINtec PLUS and the Pap smear: a co-testing alternative

I have no financial interests in any product I will discuss today.

Cervical Cancer Screening Guidelines Update

National Cervical Screening Program MBS Item Descriptors

Human papillomavirus and vaccination for cervical cancer

HPV & CERVICAL CANCER POLICY & LEGISLATIVE TOOLKIT, 3 RD EDITION

EVIDENCE REPORT. Ass.-Prof. Dr. Gaby Sroczynski, M.P.H., Univ.-Prof. Dr. Uwe Siebert, M.P.H., M.Sc.

Cervical Cancer Prevention in the 21 st Century Changing Paradigms

BC Cancer Cervix Screening 2015 Program Results. February 2018

Update on Cervical Cancer Screening. Rahmouna Farez M.D. Assistant Professor, Medical College of Wisconsin 5/2/2014

Update on Cervical Cancer Screening

Cervical Cancer Screening. David Quinlan December 2013

HPV Molecular Diagnostics and Cervical Cytology. Philip E. Castle, PhD, MPH American Society for Clinical Pathology (ASCP) March 15, 2012

Human Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?

BRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM

Epigenetic markers on the horizon: how to triage hrhpv positive women

Manitoba Cervical Cancer Screening Program. Operations & Statistical Report and 2006

Screening for the Precursors of Cervical Cancer in the Era of HPV Vaccination. Dr Stella Heley Senior Liaison Physician Victorian Cytology Service

Cervical Cancer Screening

Objectives. Disclosures. HPV: Quick Facts

Portinari: A Data Exploration Tool to Personalize Cervical Cancer Screening

QIAsure Methylation Test a breakthrough solution in Women s Health

Screening for Cervical Cancer. Grand Rounds 1/16/13 Meggan Linck

Focus. A case. I have no conflicts of interest. HPV Vaccination: Science and Practice. Collaborative effort with Karen Smith-McCune, MD, PhD 2/19/2010

Details of HPV-based Cervical Cancer Screening in Turkey

Disclosures & images

Quantitative Optical Spectroscopy of the Uterine Cervix: A cost effective way to detect and manage cervical disease

Dysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.

Cytology-based screening has been heralded as a ORIGINAL RESEARCH

Quarterly laboratory and pathology update from Legacy Laboratory Services in collaboration with Cascade Pathology

Cervical Screening Recommendation for non HIV-infected Immunosuppressed Women

ANALYSES OF CERVICAL CANCER IN RAJKOT POPULATION

Evidence-based treatment of a positive HPV DNA test. Th. Agorastos Prof. of Obstetrics & Gynaecology Aristotle University Thessaloniki/GR

ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests

Cytology Report Format

Comparing Liquid-Based Cytology Methods in the Detection of Cervical Cancer: Perspectives from Dr. Ming Guo

ASCCP Guideline Changes and Management of the Abnormal Pap Test Accurately Targeting Intervention

Lessons From Cases of Screened Women Who Developed Cervical Carcinoma

HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests

Cervical Cancer Screening Update. Melissa Hartman, DO Women s Health

CERVICAL CANCER SCREENING SCENARIOS for pan-canadian Cervical Screening Initiative

New Mexico Department of Health Influenza & Respiratory Disease Report,

Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening

!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$

Clinical Practice Guidelines June 2013

Performance of the Aptima High-Risk Human Papillomavirus mrna Assay in a Referral Population in Comparison with Hybrid Capture 2 and Cytology

THE PERFORMANCE OF CEPHEID XPERT HPV

Multimodal Spectroscopic Imaging of the Cervix for Triaging Patients to Colposcopy

Cervical Dysplasia and HPV

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013

HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series

An Update on Cervical Cancer Screening Recommendations and on the DOH BCC Program

How Are We Doing with Cervical Cancer Screening in the U.S.?

Aims for public health surveillance of the HPV programme in Scotland

Update on HPV Testing. Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories

L impact attendu de la vaccination contre le virus du papillome humain sur les pratiques de dépistage du cancer du col uterin

The society for lower genital tract disorders since 1964.

Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation?

The Korean Journal of Cytopathology 15 (1) : 17-27, 2004

The Future of Cervical Screening. Jenny Ross

Should Anal Pap Smears Be a Standard of Care in HIV Management?

Cervical Cancer Screening - Improving PAP Rates. Objectives


10/20/2015. Valerie Ballard, DNP Women s Health Nurse Practitioner

Management of Abnormal Cervical Cytology and Histology

HPV Primary Screening Update. Prof. Vu Ba Quyet Director of NO&G hospital

Bottoms UP HIV and Anal Cancer from Screening to Prevention

Absolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women

Human Papillomavirus Genotypes and the Cumulative 2-Year Risk of Cervical Precancer

ICD-9-CM to ICD-10-CM DIAGNOSIS CODE MAPPING. Central Valley Public Health: Women's Way

Human Papillomavirus (HPV) and Cervical Cancer Prevention

Disclosures Teresa M Darragh, MD

Transcription:

Population Effectiveness of HPV Vaccination on Cervical Cancer Prevention in the U.S. Project #3 Cosette M. Wheeler, Ph.D. - Leader Woman-based informatics program that captures all events and outcomes of a US population-based cervical screening program to define implementation and effectiveness of primary (vaccine) and secondary (Pap & HPV tests) HPV interventions

Timeline Effect of HPV Vaccination on Cervical Cancer: The Promise of Global Cervical-Cancer Prevention Schiffman and Castle. NEJM. 2005

New Mexico HPV Pap Registry NMHPVPR A partnership of local, national and federal organizations, agencies and content experts

7 NMAC 4.3.12 Notifiable Diseases and Conditions 4/15/06 and 4/15/09 Mandated Reporting Title: Health Chapter 4: Disease Control (Epidemiology) Part 3: Control of Disease and Conditions of Public Health Significance Laboratories report the following tests to designee: Papanicolaou test results (all results) Cervical, vulvar and vaginal pathology results (all results) HPV test results (all results)

Current Reporting New Mexico Laboratory State-wide Distribution ~610,000 women base Reporting is 99% EMR, 95% all NM residents screening Includes labs outside of NM representing <20% of all tests National Labs Quest Ameripath Labcorp ARUP Texas Labs CDD Cytolabs Mattison

New Mexico HPV Pap Registry Data Flow Diagram Santa Fe Las Cruces NM-SEER NM-SIIS Roswell State-wide, Regional and National Lab Reporting Albuquerque Rio Rancho Internet Application Server Staging Database Carlsbad Farmington Gallup Health Plans Medicare Production Database

MEMORANDUM OF AGREEMENT BETWEEN THE UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER AND THE NEW MEXICO DEPARTMENT OF HEALTH

UNM-IHPC Project #3 - Aims Aim 1: To establish overall and HPV genotype-specific incidence rates of cervical intraepithelial neoplasia (CIN) in the screened population as a baseline to which future cohorts with increasing proportions of HPV vaccinated women can be compared Aim 2: To define the impact of HPV vaccination on the populationbased incidence of CIN Aim 3: To delineate the impact of HPV vaccination on HPV genotype frequency as an early measure of HPV vaccine effectiveness Aim 4: To define cervical screening practices and effectiveness in the NM population over the time period 2006-2013 and to reveal any changes potentially related to HPV vaccine uptake

Number of Pap Tests by Age 2006-2007 40000 35000 30000 25000 20000 15000 10000 5000 0 10 20 30 40 50 60 70 80 90 100 Age

Positive for HPV HPV by Age Normal Pap 50% 40% Any HPV High risk HC2 16 or 18 Low risk HC2 30% 20% 10% 0% 10 20 30 40 50 60 70 Age

Cumulative Percent Number of Days Between Pap and Biopsy All New Mexico Labs by Cytologic Diagnosis Pap Test in 2006, Biopsies through 2007 100 90 80 HSIL AGUS ASC-H LSIL ASCUS+ ASCUS- 70 60 50 40 30 20 10 0 0 30 60 90 120 150 180 210 240 270 300 330 360 Days to Biopsy

HPV Viral Ecology Surveillance Research Component Population-based HPV type-specific testing IRB approved health research Designed to precisely detect changes in HPV type-specific prevalence and impact on disease outcomes pre- and postvaccination ~20,000 liquid cytology samples/month Honest broker de-identified Target ( 30yrs) 30,000 normal randomly sampled 10,000 abnormal Target (all ages) 4,000 CIN1 and 4,000 CIN2/3

HPV Genotyping Study New Mexico State-Wide Population Baseline Total Pap Tests 1 In Study Labs 2 Specimens Selected 3 Specimens Located 4 HPV Genotyping 5 Age Pap Diagnosis N N (%) N (%) N (%) N (%) <=30 Abnormal 17785 13769 (77%) 13668 (77%) 12397 (70%) 10881 (61%) Normal 109449 79568 (73%) 37571 (34%) 34422 (31%) 29037 (27%) > 30 Abnormal 13298 11144 (84%) 11063 (83%) 9865 (74%) 8644 (65%) Normal 216634 177240 (82%) 13242 (6%) 12384 (6%) 11994 (5%) Total 357166 281721 (79%) 75544 (21%) 69068 (19%) 60556 (17%)

Project # 3 Directions and Opportunities for Collaboration Model laboratory-based medical informatics program enabling comparative effectiveness of US cervical screening and HPV vaccination amenable to implementation in other settings Defines real-world clinical practice and impact of interventions vs. guidelines and expected Teaches natural language parsing of dictated text diagnoses Allows geospatial mapping and targeting of disparities Population-based cervical sample and data resource is amenable to other IRB approved research use and biorepository could be used to assess other STIs